Drug
Copanlisib clinical trials
Also written BAY 80-6946 and Aliqopa.
Includes 8 studies of Copanlisib hydrochloride.
- studies test it
- 66
- open now
- 0
- in phase 3
- 3
- first study started
- 2009
How studies write it
Studies that test it under each name
Studies by the year they started
66 studies that test it; most in 2018 (11)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 1 |
| 2018 | 11 |
| 2019 | 11 |
| 2020 | 11 |
| 2021 | 6 |
| 2022 | 6 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 41
- Phase 2
- 36
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 47
Bayer (19) · National Cancer Institute (NCI) (14) · Memorial Sloan Kettering Cancer Center (4) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (2) · Cancer Trials Ireland (2) · Columbia University (2) · University of Washington (2)
Often tested with
Tested in the same studies.
Nivolumab (7) · Rituximab (5) · Venetoclax (4) · Ado-Trastuzumab Emtansine (3) · Durvalumab (3) · Olaparib (3) · Fulvestrant (3) · Ibrutinib (3)
Studies
Open first, then newest update. How each study uses copanlisib is read from its arms, and is right about nine times in ten.
Testing it · 66
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Copanlisib
- Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06360588Written as Copanlisib
- Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03842228Written as Copanlisib Hydrochloride
- Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03939897Written as Copanlisib Hydrochloride
- Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingPhase 1City of Hope Medical CenterNCT03884998Written as Copanlisib
- Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04345913Written as Copanlisib Hydrochloride
- Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCLCompletedPhase 2University Hospital MuensterNCT04263584Written as Copanlisib
- Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT03586661Written as Copanlisib
- Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06400238Written as Copanlisib
- Copanlisib and Rituximab in Marginal Zone Lymphoma PatientsActive, not recruitingPhase 2Christian BuskeNCT03474744Written as Copanlisib
- Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT05490771Written as Copanlisib Hydrochloride
- Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingPhase 1/2City of Hope Medical CenterNCT04939272Written as Copanlisib Hydrochloride
- Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)CompletedPhase 1Cancer Trials IrelandNCT02705859Written as Copanlisib
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular LymphomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03789240Written as Copanlisib
- Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)CompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03581942Written as Copanlisib
- Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTerminatedPhase 2M.D. Anderson Cancer CenterNCT05082025Written as Copanlisib
- Copanlisib Plus Venetoclax in R/R DLBCLActive, not recruitingPhase 1/2Dana-Farber Cancer InstituteNCT04572763Written as Copanlisib
- Lung Cancer With Copanlisib and DurvalumabCompletedPhase 1Zhonglin HaoNCT04895579Written as Copanlisib
- Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)CompletedPhase 3BayerNCT02367040Written as Copanlisib (Aliqopa, BAY80-6946)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT04108858Written as Copanlisib
See all 66 studies that test copanlisib →
Given in every arm · 5 — copanlisib is usual care beside what is tested
- Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03502733Written as Copanlisib
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04317105Written as Copanlisib Hydrochloride
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedPhase 1Mayo ClinicNCT03432741Written as Copanlisib Hydrochloride
- Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerTerminatedPhase 1Jonsson Comprehensive Cancer CenterNCT03128619Written as Copanlisib
- Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced CancerCompletedPhase 1BayerNCT01460537Written as BAY80-6946
As the comparator · 1 — what is tested is compared with copanlisib
Codes
What other systems call copanlisib · ClinicalTrials.gg INT000019
- MeSH (NLM) C000589253copanlisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) WI6V529FZ9COPANLISIBConfirmed FDA, NLM, Wikidata
- RxNorm 1945077One source FDA
- Wikidata Q19903876copanlisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96796CopanlisibOne source FDA
- DrugBank DB12483One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000589253 | copanlisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | WI6V529FZ9 | COPANLISIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1945077 | — | One source FDA |
| Wikidata | Q19903876 | copanlisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96796 | Copanlisib | One source FDA |
| DrugBank | DB12483 | — | One source Wikidata |
Also registered as copanlisib hydrochloride hydrate (UNII W421JK3CPA).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.